Global Vagus Nerve Stimulation Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143052
- Pages: 225
-
Format:
Short Description
Global Vagus Nerve Stimulation Market, By Product Type (Implantable VNS Devices and External VNS Devices), Biomaterial (Ceramics, Metallic, and Polymerics), Application (Pain Management, Epileptic Seizures, Obesity Management, Depression and Anxiety, and Others), Patient Type (Adults, Pediatric, and Geriatric), End User (Hospitals, Ambulatory Surgical Centers, Specialty Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Philippines, Indonesia, Rest of Asia-Pacific, UAE, Israel, South Africa, Saudi Arabia, Egypt, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America) Industry Trends and Forecast to 2029.
Market Definition
The vagus nerve is a long cranial nerve that runs from a persons brain stem into the neck, chest, and abdomen. It is a part of the parasympathetic nervous system, which is commonly referred to as the rest-and-digest system because it regulates bodily functions while a person is at rest. It delivers messages to a persons brain from their digestive system and organs such as their lungs, heart, and liver. It controls several organ functions, including digestion, heart rate, and respiratory rate. It is responsible for vasomotor activity and reflexes. It also regulates vocalization, mood, and immunity. It influences sensory functions in a persons ears, sinuses, and esophagus as well.
Vagus Nerve Stimulation (VNS) involves a pulse generator inserted under a persons skin on their chest. The implantable device, which is similar to a pacemaker, delivers regular electrical pulses to the brain via the vagus nerve. It is possible to provide additional stimulation by placing the provided magnet over the pulse generator. Relaxation techniques such as breathing exercises, yoga, and medication can influence vagus nerve activity, increasing its ability to relieve anxiety and mood-related symptoms. VNS can improve an individuals physical health and can offer benefits for several conditions such as epilepsy and depression. The treatment has a healing effect on a persons body due to its ability to promote relaxation and reduce inflammation.
Market Segmentation
Global vagus nerve stimulation market is categorized into six notable segments based on product type, biomaterial, application, patient type, end user, and distribution channel.
Based on product type, the market is segmented into implantable VNS devices and external VNS devices
Based on biomaterial, the market is segmented into ceramics, metallic, and polymerics
Based on application, the market is segmented into pain management, epileptic seizures, obesity management, depression and anxiety, and others
Based on patient type, the market is segmented into adults, pediatrics, and geriatrics
Based on end user, the market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others
Based on distribution channel, the market is segmented into direct tender, retail sales, and others
Market Players
Some of the key market players in the global vagus nerve stimulation market are listed below:
electroCore, Inc.
LivaNova PLC
Medtronic
SetPoint Medical
tVNS Technologies GmbH
MicroTransponder Inc.
Others
TABLE OF CONTENTS
1 INTRODUCTION 41
1.1 OBJECTIVES OF THE STUDY 41
1.2 MARKET DEFINITION 41
1.3 OVERVIEW OF GLOBAL VAGUS NERVE STIMULATION MARKET 41
1.4 LIMITATIONS 43
1.5 MARKETS COVERED 43
2 MARKET SEGMENTATION 45
2.1 MARKETS COVERED 45
2.2 GEOGRAPHICAL SCOPE 46
2.3 YEARS CONSIDERED FOR THE STUDY 47
2.4 CURRENCY AND PRICING 47
2.5 DBMR TRIPOD DATA VALIDATION MODEL 48
2.6 MULTIVARIATE MODELLING 51
2.7 LIFELINE CURVE , BY PRODUCT TYPE 51
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 52
2.9 DBMR MARKET POSITION GRID 53
2.10 MARKET APPLICATION COVERAGE GRID 54
2.11 VENDOR SHARE ANALYSIS 55
2.12 SECONDARY SOURCES 56
2.13 ASSUMPTIONS 56
3 EXECUTIVE SUMMARY 57
4 PREMIUM INSIGHTS 60
4.1 PORTERS FIVE FORCES 63
4.2 PESTEL ANALYSIS 64
4.3 KEY STRATEGIC INITIATIVES 65
5 REGULATIONS OF GLOBAL VAGUS NERVE STIMULATION MARKET 66
6 MARKET OVERVIEW 70
6.1 DRIVERS 72
6.1.1 INCREASING PREVALENCE AND INCIDENCE OF NEUROLOGICAL DISORDERS 72
6.1.2 INNOVATIVE NON-INVASIVE VAGUS NERVE STIMULATION DEVICES INTRODUCED TO MEET DEMAND 73
6.1.3 RISE IN PRODUCT APPROVALS 73
6.1.4 PRODUCT DEVELOPMENT IN RECENT YEARS 74
6.2 RESTRAINTS 74
6.2.1 HIGH MAINTENANCE AND DEVICE COSTS TO RESTRAIN ADOPTION OF VAGUS NERVE STIMULATORS 74
6.2.2 RISE IN PRODUCT RECALL 75
6.2.3 UNFAVORABLE REIMBURSEMENT POLICIES 75
6.3 OPPORTUNITIES 76
6.3.1 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS 76
6.3.2 RISING GOVERNMENT INITIATIVES FOR NEUROLOGICAL DISEASE 76
6.4 CHALLENGES 77
6.4.1 RISKS ASSOCIATED WITH THE IMPLANTATION OF THESE DEVICES 77
6.4.2 LACK OF SKILLED HEALTHCARE PROFESSIONALS 77
6.4.3 STRINGENT REGULATIONS FOR APPROVAL OF MEDICAL DEVICES 78
7 GLOBAL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE 79
7.1 OVERVIEW 80
7.2 IMPLANTABLE VNS DEVICE 83
7.3 EXTERNAL VNS DEVICE 83
8 GLOBAL VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL 84
8.1 OVERVIEW 85
8.2 METALLIC 88
8.3 POLYMERIC 88
8.4 CERAMICS 89
9 GLOBAL VAGUS NERVE STIMULATION MARKET, BY APPLICATION 90
9.1 OVERVIEW 91
9.2 EPILEPTIC SEIZURES 94
9.2.1 IMPLANTABLE VNS DEVICE 94
9.2.2 EXTERNAL VNS DEVICE 94
9.3 DEPRESSION AND ANXIETY 94
9.3.1 IMPLANTABLE VNS DEVICE 95
9.3.2 EXTERNAL VNS DEVICE 95
9.4 PAIN MANAGEMENT 96
9.4.1 IMPLANTABLE VNS DEVICE 96
9.4.2 EXTERNAL VNS DEVICE 96
9.5 OBESITY MANAGEMENT 97
9.5.1 IMPLANTABLE VNS DEVICE 97
9.5.2 EXTERNAL VNS DEVICE 97
9.6 OTHERS 98
10 GLOBAL VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE 99
10.1 OVERVIEW 100
10.2 ADULTS 103
10.2.1 IMPLANTABLE VNS DEVICES 103
10.2.2 EXTERNAL VNS DEVICES 103
10.3 GERIATRIC 104
10.3.1 IMPLANTABLE VNS DEVICES 104
10.3.2 EXTERNAL VNS DEVICES 104
10.4 PEDIATRIC 105
10.4.1 IMPLANTABLE VNS DEVICES 105
10.4.2 EXTERNAL VNS DEVICES 105
11 GLOBAL VAGUS NERVE STIMULATION MARKET, BY END USER 106
11.1 OVERVIEW 107
11.2 SPECIALTY CENTERS 110
11.3 HOSPITALS 110
11.4 AMBULATORY SURGICAL CENTERS (ASCS) 111
11.5 OTHERS 111
12 GLOBAL VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL 112
12.1 OVERVIEW 113
12.2 DIRECT TENDER 116
12.3 RETAIL SALES 116
12.4 OTHERS 117
13 GLOBAL VAGUS NERVE STIMULATION MARKET, BY REGION 118
13.1 OVERVIEW 119
13.2 NORTH AMERICA 124
13.2.1 U.S. 132
13.2.2 CANADA 136
13.2.3 MEXICO 140
13.3 EUROPE 144
13.3.1 GERMANY 152
13.3.2 U.K. 156
13.3.3 ITALY 160
13.3.4 SPAIN 164
13.3.5 FRANCE 168
13.3.6 SWITZERLAND 172
13.3.7 BELGIUM 176
13.3.8 NETHERLANDS 180
13.3.9 RUSSIA 184
13.3.10 TURKEY 188
13.3.11 REST OF EUROPE 192
13.4 ASIA-PACIFIC 193
13.4.1 CHINA 202
13.4.2 JAPAN 206
13.4.3 SOUTH KOREA 210
13.4.4 INDIA 214
13.4.5 AUSTRALIA 218
13.4.6 SINGAPORE 222
13.4.7 THAILAND 226
13.4.8 MALAYSIA 230
13.4.9 INDONESIA 234
13.4.10 PHILIPPINES 238
13.4.11 REST OF ASIA-PACIFIC 242
13.5 SOUTH AMERICA 243
13.5.1 BRAZIL 251
13.5.2 ARGENTINA 255
13.5.3 COLOMBIA 259
13.5.4 REST OF SOUTH AFRICA 263
13.6 MIDDLE EAST AND AFRICA 264
13.6.1 SOUTH AFRICA 272
13.6.2 UAE 276
13.6.3 EGYPT 280
13.6.4 SAUDI ARABIA 284
13.6.5 ISRAEL 288
13.6.6 REST OF MIDDLE EAST AND AFRICA 292
14 GLOBAL VAGUS NERVE STIMULATION MARKET: COMPANY LANDSCAPE 293
14.1 COMPANY SHARE ANALYSIS: GLOBAL 293
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 294
14.3 COMPANY SHARE ANALYSIS: EUROPE 295
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 296
15 SWOT ANALYSIS 297
16 COMPANY PROFILE 298
16.1 ELECTROCORE, INC. 298
16.1.1 COMPANY SNAPSHOT 298
16.1.2 REVENUE ANALYSIS 298
16.1.3 COMPANY SHARE ANALYSIS 299
16.1.4 PRODUCT PORTFOLIO 299
16.1.5 RECENT DEVELOPMENTS 299
16.2 LIVANOVA PLC 301
16.2.1 COMPANY SNAPSHOT 301
16.2.2 REVENUE ANALYSIS 301
16.2.3 COMPANY SHARE ANALYSIS 302
16.2.4 PRODUCT PORTFOLIO 302
16.2.5 RECENT DEVELOPMENTS 302
16.3 MEDTRONIC 304
16.3.1 COMPANY SNAPSHOT 304
16.3.2 REVENUE ANALYSIS 304
16.3.3 COMPANY SHARE ANALYSIS 305
16.3.4 PRODUCT PORTFOLIO 305
16.3.5 RECENT DEVELOPMENTS 305
16.4 SETPOINT MEDICAL 306
16.4.1 COMPANY SNAPSHOT 306
16.4.2 COMPANY SHARE ANALYSIS 306
16.4.3 PRODUCT PORTFOLIO 307
16.4.4 RECENT DEVELOPMENTS 307
16.5 TVNS TECHNOLOGIES GMBH 308
16.5.1 COMPANY SNAPSHOT 308
16.5.2 COMPANY SHARE ANALYSIS 308
16.5.3 PRODUCT PORTFOLIO 309
16.5.4 RECENT DEVELOPMENT 309
16.6 NEUROPIX COMPANY LTD. 310
16.6.1 COMPANY SNAPSHOT 310
16.6.2 PRODUCT PORTFOLIO 310
16.6.3 RECENT DEVELOPMENT 310
16.7 BRAIN CONTROL CO. LTD 311
16.7.1 COMPANY SNAPSHOT 311
16.7.2 PRODUCT PORTFOLIO 311
16.7.3 RECENT DEVELOPMENTS 311
16.8 CIRTEC 312
16.8.1 COMPANY SNAPSHOT 312
16.8.2 PRODUCT PORTFOLIO 312
16.8.3 RECENT DEVELOPMENTS 312
16.9 MICROTRANSPONDER INC. 313
16.9.1 COMPANY SNAPSHOT 313
16.9.2 PRODUCT PORTFOLIO 313
16.9.3 RECENT DEVELOPMENT 313
16.10 PARASYM LTD 314
16.10.1 COMPANY SNAPSHOT 314
16.10.2 PRODUCT PORTFOLIO 314
16.10.3 RECENT DEVELOPMENT 314
16.11 RESHAPE LIFESCIENCES INC. (2021) 315
16.11.1 COMPANY SNAPSHOT 315
16.11.2 REVENUE ANALYSIS 315
16.11.3 PRODUCT PORTFOLIO 316
16.11.4 RECENT DEVELOPMENT 316
16.12 SOTERIX MEDICAL INC. 317
16.12.1 COMPANY SNAPSHOT 317
16.12.2 PRODUCT PORTFOLIO 317
16.13 RECENT DEVELOPMENTS 317
17 QUESTIONNAIRE 318
18 RELATED REPORTS 321
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
